May 8th 2021, 8:01pm
Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.
May 8th 2021, 3:54pm
The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.
May 8th 2021, 10:45am
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.
May 8th 2021, 10:29am
Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.
May 8th 2021, 1:02am
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.
May 7th 2021, 10:16pm
Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.
May 7th 2021, 9:42pm
Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
May 7th 2021, 9:08pm
Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.
May 7th 2021, 5:30pm
Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.
May 7th 2021, 2:09pm
Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.